Literature DB >> 10762079

Coimmunization with IFN-gamma or IL-2, but not IL-13 or IL-4 cDNA can enhance Th1-type DNA vaccine-induced immune responses in vivo.

J J Kim1, J S Yang, L Montaner, D J Lee, A A Chalian, D B Weiner.   

Abstract

As we explore the potential improvements to the current DNA vaccine strategies, it may be desirable to investigate methods to improve the level of resulting immune responses. One strategy is the use of cytokine cDNA as molecular adjuvants for DNA-based vaccines. Codelivery of these molecular adjuvants consisting of expression plasmid encoding for cytokines with DNA vaccine constructs is an effective method to modulate the magnitude and direction (humoral or cellular) of the immune responses. We have previously reported on the immunomodulatory effects of codelivering cDNA for interleukin-2 (IL-2) and IL-4 as molecular adjuvants for DNA-based vaccines. In this report, we extend these finding and compare the immunomodulatory effects of IL-2 and IL-4 with those of cDNA for prototypical Thl-type cytokine interferon-y (IFN-gamma) and Th2-type cytokine IL-13. We observed that distinct antigen-specific immune modulation can be achieved by the coinjection of IFN-gamma or IL-13 genes with DNA immunogen cassettes. We observed that IFN-gamma is a strong driver of Thl immune responses. Furthermore, in contrast to previous reports on their similarities in biologic activities, IL-13 and IL-4 cDNA coimmunizations modulated vaccine-induced immune responses differently in this model. Overall, these results further support the potential utility of this strategy as an important tool for the development of vaccines and immune therapies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10762079     DOI: 10.1089/107999000312450

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  19 in total

Review 1.  Technologies for enhanced efficacy of DNA vaccines.

Authors:  Fadi Saade; Nikolai Petrovsky
Journal:  Expert Rev Vaccines       Date:  2012-02       Impact factor: 5.217

2.  DNA vaccines expressing different forms of simian immunodeficiency virus antigens decrease viremia upon SIVmac251 challenge.

Authors:  Margherita Rosati; Agneta von Gegerfelt; Patricia Roth; Candido Alicea; Antonio Valentin; Marjorie Robert-Guroff; David Venzon; David C Montefiori; Phil Markham; Barbara K Felber; George N Pavlakis
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

Review 3.  DNA vaccines: developing new strategies to enhance immune responses.

Authors:  Shaheed A Abdulhaqq; David B Weiner
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

Review 4.  Selected approaches for increasing HIV DNA vaccine immunogenicity in vivo.

Authors:  Natalie A Hutnick; Devin J F Myles; Chaoran Billie Bian; Karuppiah Muthumani; David B Weiner
Journal:  Curr Opin Virol       Date:  2011-09-07       Impact factor: 7.090

5.  An M2 Rather than a TH2 Response Contributes to Better Protection against Latency Reactivation following Ocular Infection of Naive Mice with a Recombinant Herpes Simplex Virus 1 Expressing Murine Interleukin-4.

Authors:  Dhong Hyun Lee; Homayon Ghiasi
Journal:  J Virol       Date:  2018-04-27       Impact factor: 5.103

6.  SIV antigen-specific effects on immune responses induced by vaccination with DNA electroporation and plasmid IL-12.

Authors:  Ross W Lindsay; Ian Ouellette; Heather E Arendt; Jennifer Martinez; Joanne DeStefano; Mary Lopez; George N Pavlakis; Maria J Chiuchiolo; Christopher L Parks; C Richter King
Journal:  Vaccine       Date:  2013-08-14       Impact factor: 3.641

7.  Recombinant herpes simplex virus type 1 (HSV-1) codelivering interleukin-12p35 as a molecular adjuvant enhances the protective immune response against ocular HSV-1 challenge.

Authors:  Yanira Osorio; Homayon Ghiasi
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

8.  Adjuvant activity of the catalytic A1 domain of cholera toxin for retroviral antigens delivered by GeneGun.

Authors:  Kenneth C Bagley; George K Lewis; Timothy R Fouts
Journal:  Clin Vaccine Immunol       Date:  2011-04-20

9.  Comparison of adjuvant efficacy of herpes simplex virus type 1 recombinant viruses expressing TH1 and TH2 cytokine genes.

Authors:  Yanira Osorio; Homayon Ghiasi
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

Review 10.  Cytokine production and dysregulation in HIV pathogenesis: lessons for development of therapeutics and vaccines.

Authors:  Morgan A Reuter; Carolina Pombo; Michael R Betts
Journal:  Cytokine Growth Factor Rev       Date:  2012-06-27       Impact factor: 7.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.